16 results about "Cytokeratin" patented technology

The invention provides an automatic tumor budding identification method fusing pathological staining migration and YOLO target detection. The method comprises the following steps: training Hamp by using a CUT model; a staining migration model is established from the E image to the immunohistochemical image, and the staining migration model is utilized to carry out Hamp; e, converting the dyed full-width pathological section into a cytokeratin dyed full-width pathological section; and performing tumor budding detection on the generated full-width pathological section dyed by the cytokeratin by using a TB-YOLO model improved on the basis of YOLOv10. According to the method, the CUT is combined for pathological image staining migration, the IHC image generated through TB-YOLO analysis is used for tumor budding detection, meanwhile, accurate translation and detection of positive signals are ensured, richer diagnosis information is provided for pathologists, the diagnosis accuracy is improved, the pathological examination cost of patients is reduced, and the purpose that only Hamp is used for diagnosis is achieved. And E, the tumor budding is accurately detected by the dyed image, so that the comparability of medical images in different dyeing modes and the applicability of a cross-dyeing method are improved.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The present invention relates to citrullinated Cytokeratin peptides that can be used in cancer immunotherapy. The modified peptides may be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies. Such vaccines or targets may be used in the treatment of cancer.

The invention relates to a 177Lu-DOTATATE peptide receptor radionuclide curative effect prediction model and application thereof, the model is used for performing multicolor immunofluorescent staining on tissue slices of a neuroendocrine tumor (NET) patient, and the model at least comprises specific staining antibodies of cytokeratin (CK +) cells, CD8 cells and TIM-3 molecules; then carrying out image acquisition and analysis, and identifying two positive cells, namely CK < + > and CD8 < + > TIM-3 < + >; calculating an under-curve area difference AUC (CK) (CD8 + TIM-3 +) between an observation curve of a nearest neighbor distance accumulation function (G function) between CK + and CD8 + TIM-3 + and a Poisson distribution curve according to an R language software package, determining a response scoring formula and threshold division based on single-factor logistic regression of PRRT response degree of case data, and substituting the difference into the response scoring formula, and the response score can be used for curative effect prediction.

The present disclosure relates to aptamers that specifically bind to Cytokeratin 8 (CK8) and / or Cytokeratin 18 (CK18) and their use as biomarkers for the detection of cancer, preferably carcinoma or adenocarcinoma. The present disclosure also relates to an intraoperative surgical pathology method that provides for the rapid identification of cancer cells, in particular carcinoma or adenocarcinoma, in a biological sample.

The present invention relates to the use of the use of a blend of sugars comprising psicose, mannose, fructose and glucose to increase the expression of cytokeratin-1 in skin to strengthen skin's self-defense mechanisms and maintain skin integrity.

A TPS CLIA kit comprises an immunoconjugate comprising an alkaline phosphatase conjugated to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to one of the M3 and M21 epitopes of cytokeratin 18, a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to other of the M3 and M21 epitopes, a substrate of alkaline phosphatase and a solid support. The monoclonal antibody, or the antigen-binding fragment thereof, binding specifically to other of the M3 and M21 epitopes is immobilized or is intended to be immobilized to the solid support. The invention also relates to a method for detecting TPS in a sample using the TPS CLIA kit.

The present invention is in the fields of diagnostics and treatment of cancer. The present invention provides, inter alia, means and methods for detecting and / or isolating metastasis founder cells based on the expression or expression level of the marker(s) c-KIT and / or MUC1, and, preferably, at least one additional disseminated cancer cell (DCC) marker such as EpCAM and / or (a) cytokeratin(s). Corresponding isolated cells or cell populations, and uses thereof, are provided as well. In one aspect, the invention relates to a method for detecting metastasis founder cells in a sample, comprising measuring in single cells in a sample the expression or expression level of (i) a first marker which is c-KIT and (ii) at least one disseminated cancer cell (DCC) marker, wherein expression of c-KIT and at least one DCC marker in a cell is indicative of the cell being a metastasis founder cell, or wherein expression levels of c-KIT and at least one DCC marker in a cell above respective thresholds are indicative of the cell being a metastasis founder cell. Furthermore, the invention relates to methods for prognosing the development of metastases and / or the relapse, progression or outcome of a cancer, as well as to methods for measuring the success of an anti-cancer treatment and / or for stratifying subjects for treatment with (an) anti-cancer drug(s), based on the expression or expression level of said marker(s) in single cells. In addition, the present invention relates to one or more anti-cancer drugs for use in treating a patient having metastasis founder cells according to the invention. Further provided are therapeutics for targeting metastasis founder cells such as antibodies or fragments thereof binding both, c-KIT and EpCAM, or CAR-T cells targeting both, c-KIT and EpCAM.

Abstract A method for detecting a biological marker in a sample, preferably a biological marker on a cancer cell, the method comprising: (i) contacting the sample with at least one DNA aptamer coupled to a first reagent and wherein the aptamer specifically binds to a first biological marker in the sample to form a first complex; (ii) contacting the first complex of (i) with a second binding agent that specifically binds to the first reagent such that a second complex is formed, wherein the second binding agent is coupled to a reporter molecule; (iii) contacting the second complex (ii) with a substrate for the reporter molecule of the at least one second binding agent; and (iv) detecting the substrate reaction by formation of a reaction product thereby detecting the biological marker in the sample. Biological markers include cytokeratin 8 (CK8), cytokeratin 18 (CK18), human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM). Abstract 41 / 50 FIGURE 40 Frozen section preparation 4 Sample fixation + Wash (10 dips in PBS) DNA aptamer staining DAB Substrate DAB substrate HRP FAM Anti-FITC conjugated with HRP FAM DNA Aptamer conjugated with FAM HRP Frozen section slide / Touch imprint slide / Cytology slide / Direct smear slide Anti-FITC-HRP Wash (10 dips in PBS) DAB Wash (10 dips in PBS) Hematoxylin counter-staining Wash under tap water Cove rs lip DAB brown precipitate at the location of the aptamer B o min 1 min 15 sec 5 min 15 sec 5 min 15 sec 5 min 15 sec 10 sec 1 min 1 min A + Wash (10 dips in PBS) Total time for aptamer-DAB staining: —18 min 4 1 / 5 0 A B 1 0 m i n 1 m i n D A B s u b s t r a t e 1 5 s e c H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n 1 5 s e c D N A A p t a m e r c o n j u g a t e d w i t h F A M 5 m i n D A B W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 020 25 28 36 33 19 D ec 2 02 5 1 9 D e c 2 0 2 5 A B 1 0 m i n F r o z e n s e c t i o n p r e p a r a t i o n 1 m i n S a m p l e f i x a t i o n D A B 2 0 2 5 2 8 3 6 3 3 s u b s t r a t e 1 5 s e c W a s h ( 1 0 d i p s i n P B S ) H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n A n t i - F I T C - H R P T o t a l t i m e f o r 1 5 s e c D N A A p t a m e r W a s h ( 1 0 d i p s i n P B S ) c o n j u g a t e d w i t h F A M 5 m i n D A B s t a i n i n g : ~ 1 8 m i n W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / 1 0 s e c H e m a t o x y l i n C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 0

The invention relates to a method for predicting the progress from acute kidney injury to chronic kidney disease, and belongs to the field of medical prediction. The method comprises the following steps: constructing a clinical model containing age, gender, baseline serum creatinine, urinary albumin creatinine ratio and discharged serum creatinine; fitting the nonlinear relationship between the acute kidney injury staging and the chronic kidney disease progress by adopting a restrictive cubic spline function; detecting the level of cytokeratin 20 in urine to construct a biomarker model; and combining Logistic regression to analyze the nonlinear correlation between the cytokeratin 20 in the urine and the progress of the chronic kidney disease, and evaluating the performance of the model. Conventional clinical indexes and cytokeratin 20 in urine are integrated, and extra detection is not needed; the nonlinear relation between the acute kidney injury staging and the chronic kidney disease progress is accurately described by using a cubic spline function, and the method reduces the clinical application cost, improves the prediction efficiency, and is suitable for early risk stratification and individualized intervention.

The application discloses a method and a kit for simultaneously detecting multiple proteins in liver, and belongs to the technical field of medical detection. The target proteins of the method include glutamate amino transferase 1 protein, glutamic transaminase 1 protein, methionine adenosyltransferase 1A protein, glutathione peroxidase 1 protein, cytokeratin 18 and apolipoprotein E. First, the liver tissue to be detected is subjected to pretreatment such as enzymolysis and desalination to obtain a sample solution to be detected, then nanoliter liquid chromatography-tandem mass spectrometry is used to detect six characteristic peptide segments corresponding to the target proteins in the sample solution to be detected, and the content of the corresponding target proteins is calculated according to the content of the characteristic peptide segments. The method is convenient to operate, has good selectivity, high accuracy and high sensitivity, the detection limit reaches the pg / mL level, absolute quantification of the proteins can be realized, and the method has a wide application prospect in the research and development and efficacy evaluation of anti-liver injury drugs.

A lateral flow immunometer 10 includes a sample accommodation portion 20 configured to accommodate a sample; a SERS active particle configured to bind to cytokeratin-18 (K18) in the sample, and a test portion 40 configured to immobilize the SERS active particle that has bound to K18.

This tumor microenvironment prediction method using a deep learning model comprises steps in which an analysis device: generates a cytokeratin (CK) staining image from a hematoxylin and eosin (H&E) staining image with respect to a region of interest of a sample; generates a leukocyte common antigen (LCA) staining image from the H&E staining image; generates a desmin staining image from the H&E staining image; and calculates a tumor microenvironment index for the region of interest on the basis of the CK staining image, the LCA staining image, and the desmin staining image.

Conventional, manual identification and scoring of a whole slide image (WSI) to detect Cytokeratin 17 (K17) expression has limitations in terms of lower accuracy in the medium grade cases, slower turn-around time, and high inter and intra-observer variability. Each WSI can take a pathologist six to ten minutes to examine. This is because the brown color staining indicating the presence of K17 may be one of thousands or tens of thousands or other expressions present on the slide. Apparatus and methods are provided for an artificial intelligence (AI) solution that identifies and quantifies positively stained urothelial cells in WSI of urine cytology to aid the diagnosis of urinary bladder carcinoma. An illustrative AI solution may include one or computer models that are programmed to run one more machine learning (ML) models. The ML models may be trained to recognize subtle and complex patterns and features associated with specific diseases.